Can mean platelet component be used as an index of platelet activity in stable coronary artery disease?

John Cooke1, Tracy Murphy, Eugene McFadden

  • 1Mid-Western Regional Hospital, Dooradoyle, Limerick, Ireland.

Insights

Mean platelet component (MPC) does not indicate platelet activation in stable coronary artery disease (CAD). This routine blood test measure is not useful for differentiating CAD patients from controls in clinical practice.

Area of Science:

  • Cardiology
  • Hematology
  • Clinical Pathology

Background:

  • Platelet activation is central to acute coronary syndromes and vascular disease.
  • Current platelet activation markers lack routine clinical applicability.
  • Mean Platelet Component (MPC) is a novel measure of platelet density from routine blood counts.

Purpose of the Study:

  • To assess if MPC is elevated in stable coronary artery disease (CAD).
  • To evaluate MPC's utility in distinguishing stable CAD patients from controls.
  • To determine MPC's role in everyday clinical practice for CAD assessment.

Main Methods:

  • Prospective study of 345 patients undergoing elective coronary angiography.
  • Full blood count and MPC measurement using an ADVIA-120 analyser.
  • Analysis of 324 patients, with 253 diagnosed with CAD.

Main Results:

  • No significant difference in MPC between patients with CAD and controls (p=0.467).
  • No correlation found between MPC and CAD severity (Kendall's tau b=-0.086, p=0.04).
  • CAD patients were significantly older than controls (63.8 vs 56.0 years, p<0.001).

Conclusions:

  • MPC is not a reliable indicator of platelet activity in stable CAD.
  • MPC measurement is not clinically useful for differentiating stable CAD patients.
  • Current routine blood count parameters do not reflect platelet activation in stable CAD.

Related Concept Videos

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...